Thursday, April 21, 2016

BRIEF-FDA staff maintains negative outlook on Sarepta's DMD drug

* FDA staff says it does not agree with Sarepta's

characterization of inaccuracies in the initial FDA briefing

document

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)